SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) — Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is embroiled in a securities class action lawsuit, alleging the company misled investors about its pricing practices for its blockbuster drug Eylea. The lawsuit, filed in the Southern District of New York, seeks to represent investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024.
Hagens Berman urges investors who purchased Regeneron shares and suffered substantial losses to submit your losses now.
Class Period: Nov. 2, 2023 – Oct. 30, 2024
Lead Plaintiff Deadline: Mar. 10, 2025
Visit: www.hbsslaw.com/investor-fraud/regn
Contact the Firm Now: REGN@hbsslaw.com
844-916-0895
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:
At the heart of the controversy is Regeneron’s alleged practice of paying credit card fees to distributors, on the condition that these fees were …
